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ABSTRACT
DNA is susceptible of being damaged by chemicals,
UV light or gamma irradiation. Nuclear DNA damage
invokes both a checkpoint and a repair response. By
contrast, little is known about the cellular response
to mitochondrial DNA damage. We designed an
experimental system that allows organelle-specific
DNA damage targeting in Saccharomyces cerevi-
siae. DNA damage is mediated by a toxic topo-
isomerase I allele which leads to the formation of
persistent DNA single-strand breaks. We show that
organelle-specific targeting of a toxic topoisom-
erase I to either the nucleus or mitochondria leads
to nuclear DNA damage and cell death or to loss of
mitochondrial DNA and formation of respiration-
deficient ‘petite’ cells, respectively. In wild-type
cells, toxic topoisomerase I–DNA intermediates are
formed as a consequence of topoisomerase I inter-
action with camptothecin-based anticancer drugs.
We reasoned that targeting of topoisomerase I to
the mitochondria of top1" cells should lead to
petite formation in the presence of camptothecin.
Interestingly, camptothecin failed to generate
petite; however, its derivative topotecan accumu-
lates in mitochondria and induces petite formation.
Our findings demonstrate that drug modifications
can lead to organelle-specific DNA damage and
thus opens new perspectives on the role of mito-
chondrial DNA-damage in cancer treatment.
INTRODUCTION
Topoisomerase I (Top1) is an enzyme required for the
release of torsional stress built up during transcription
or replication of DNA (1,2). This torsional stress is
deﬁned by an increase of negative DNA supercoils in
front of the transcription or replication machinery. Top1
releases torsional stress by changing the linking number of
the DNA. To change the linking number of DNA, Top1
cuts one DNA strand, passes the other through it and then
re-anneals the cut strand. In Saccharomyces cerevisiae
expression of the same TOP1 open reading frame (ORF)
appears to account for the nuclear and mitochondrial
Top1 activities. This idea was put forward because dele-
tion of the TOP1 ORF abolishes Top1 speciﬁc activities in
the nucleus as well as in mitochondria (3–5). In human
cells, the mitochondrial Top1 is encoded in the nuclear
genome and contains a mitochondrial localization
sequence at the N-terminus of the enzyme (6,7).
Incomplete action of Top1 has been shown to be a nat-
ural source of DNA damage such as DNA single-strand
breaks (SSBs). Persistent SSBs can be converted to lethal
double-strand breaks (DSBs) during replication (8). Single
mutations in the active center of the enzyme have been
shown to strongly increase the formation of nicked
DNA and to impair the viability of yeast cells (9,10).
This is the case for the S. cerevisiae TOP1-103 allele in
which substitution of an arginine for a lysine at amino
acid 420 generates a highly toxic Top1 isoform. A strong
increase in SSBs can also be mediated by drugs, which
trap Top1 bound to the DNA. The ancestor of such
drugs, named campthotecin [CPT; (11)], has been shown
to bind to the covalent Top1–DNA complex and form a
ternary complex impeding the ligation of cleaved DNA
(12). CPT and its derivatives are potent anticancer
drugs, which have been approved for the treatment of
solid cancers (13). Severe side eﬀects such as reversible
bone marrow depression and hemorrhagic cystitis are
major dose-limiting toxicities of CPT. New CPT analogs,
including the prodrug CPT-11 [Irinotecan; (14)] or topo-
tecan [TPT; (15)], have the advantage of higher antitumor
activity and less toxicity. However, tumor cells tend to
develop drug resistance in response to chemotherapy.
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binding cassette (ABC) transporters (16–18), as shown in
yeast or human cells.
DNA damage caused by Top1 has to be repaired to
avoid serious eﬀects on genome stability and cellular
viability. In S. cerevisiae the elimination of spontaneous
DNA lesions, such as SSBs, is mediated by many over-
lapping repair pathways. Genetic and biochemical
evidence suggests the involvement of homologous recom-
bination, base excision repair (BER), nucleotide excision
repair (NER) and substrate-speciﬁc enzymes such as the
tyrosyl-DNA phosphodiesterase Tdp1 in the removal
of the covalently bound Top1 protein from the DNA
(19–21). Although the toxic eﬀects of CPT treatment on
nuclear DNA are well studied, little is known about the
toxic eﬀects of CPT treatment on mtDNA or about spon-
taneous mtDNA lesions mediated by Top1. However,
repair enzymes and pathways that are involved in the
repair of nuclear, Top1-mediated DNA lesions also par-
ticipate in the repair of mitochondrial DNA lesions
induced by oxidative damage (22–24). One example is
the apurinic/apyrimidinic endonuclease Apn1, which
bears a bipartite nuclear localization signal. Apart from
its nuclear localization, Apn1 can be localized to the mito-
chondria upon interaction with Pir1 (25).
We reasoned that DNA nicks introduced by Top1 could
serve as a tool for the development of an experimental sys-
tem to target speciﬁc DNA damage to DNA-containing
organelles. We show that yeast cells can be poisoned
with Top1p-mediated nuclear DNA damage either by
expression of truncated, toxic TOP1-103 allele or by
expressing a truncated TOP1 allele and concomitant treat-
ment of cells with the anticancer drug CPT. Moreover,
we observe that targeting of the truncated, toxic
mt125Top1-103 to mitochondria induces the formation
of respiration-deﬁcient petite cells and mtDNA loss.
CPT treatment of cells expressing mt125Top1 protein tar-
geted to mitochondria did not induce petite formation
despite mt125Top1 puriﬁed from yeast mitochondria
being sensitive to CPT treatment in vitro. In contrast to
CPT, its analog TPT was capable of generating petite
colonies. Consistent with this ﬁnding, TPT, but not
CPT, accumulates in the mitochondria. Thus, our results
suggest that mtDNA is not accessible to CPT. Our ﬁnd-
ings show that altering the chemical properties of an antic-
ancer drug can result in organelle-speciﬁc DNA damage
targeting.
MATERIALS AND METHODS
Strainsand media
Experiments were performed in strain TOI-1Bu- (MATa
ade2-1 trp1-1 ura3-1 his3-11,15 leu2-3,112 top1::hisG
can1-100) which was kindly provided by A. Aguilera
(CABIMER, Sevilla). Yeast transformants were grown
in liquid or solid synthetic minimal medium (SC, Difco),
supplemented with amino acids and diﬀerent carbon
sources: 2% glucose, 3% glycerol-lactate, or 2% galac-
tose. Where indicated, CPT (5mg/ml stock solution in
1% DMSO, Sigma) and TPT (10mg/ml stock solution
in water, Sinova) were added to a ﬁnal concentration
of 20mg/ml.
Constructs
DNA manipulation, PCR and DNA sequencing were
performed according to standard protocols. GAL1p and
MET25p expression vectors: A 590-bp SpeI–SmaI frag-
ment of pGAL1:RNH1 (A. Aguilera, CABIMER) con-
taining the GAL1 promoter was cloned into pRS424 (26)
in order to create pRS424-GAL1p. A 716bp XbaI frag-
ment was removed from pUG34 (J.H. Hegemann,
Universita ¨ tD u ¨ sseldorf) and the GFP-less vector was
named pUG-MET25p.
Constructs containing the full-length TOP1 ORF
The ORFs of the full-length (2307bp) and truncated
(1965bp) wild-type TOP1 and mutant allele TOP1-
103 were obtained by PCR ampliﬁcation (Phusion Taq-
polymerase, Finnzymes) from plasmids pWE3 and
pNL30, respectively. Plasmids were kindly provided by
the laboratory of Dr. G. Fink (Whitehead Institute for
Biomedical Research, Cambridge, MA 02142). Primers
(Invitrogen) were tagged 50 with BglII and SmaI restric-
tion sites and the PCR fragments were cloned into pUG23
(full-length TOP1 ORF) and pUG34 (truncated 125TOP1
ORF). The GFP-125TOP1 fusion constructs were again
PCR ampliﬁed with a 50 primer matching the ﬁrst 20bp
(including a BamHI restriction site) of the GFP ORF and
a3 0 primer matching the last 20bp of the TOP1 ORF
(including an SmaI restriction site). Then the correspond-
ing PCR fragments containing the corresponding GFP-
TOP1 chimera were cloned into single BglII–SmaI or
BamHI–SmaI restriction sites of pRS424-GAL1p and
pUG-MET25p.
Constructs containing an SV40-NLS
To tag the truncated TOP1 ORF with 33bp of the
SV40-NLS, a 30 primer was designed matching the last
17bp of the TOP1 ORF (omitting the stop codon) and
having a 33-bp SV40 protruding tail (including a stop
codon and a SmaI restriction site). Then the PCR frag-
ments containing the corresponding GFP-TOP1 chimera
were cloned into single BglII–SmaI or BamHI–SmaI
restriction sites of pRS424-GAL1p and pUG-MET25p.
Constructs containing an SOD2-MLS
BamHI–SOD2–MLS–BglII or BglII–SOD2–MLS–
BamHI, 60-bp PCR fragments were ligated and cloned
into single BglII or BamHI restriction sites of vectors
pRS424-GAL1p and pUG-MET25p, respectively. Note
that upon ligation of overlapping, sticky BamHI–
BglII ends in this sequence are no longer cleavable by
either restriction enzyme. Then the corresponding PCR
fragments containing the corresponding GFP-125TOP1
chimera were cloned into single BglII–SmaI restric-
tion sites of pRS424-GAL1p-SOD2-MLS and pUG-
MET25p-SOD2-MLS. A detailed list of all vectors is
found in Table 1.
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DNA fragments were derived by PCR ampliﬁcation of
primers 50ATGACTATTGCTGATGCTTC30 and 50TTA
AAACCTCCAATTTTCAT30 (TOP1 probe), primers 50T
TGGAGAGGGCAACTTTGG30 and 50CAGGATCGG
TCGATTGTGC30 (25S rDNA probe), primers 50TGTA
TTTTCGACTCTTTG30 and 50TCAGCCAAATGAAGT
AAG30 (nuclear DNA probe), primers 50ATGTTAGATT
TATTAAGA30 and 50TTATTGTTCATTTAATCA30
(mtCOX2 probe). The mtCOX2 containing plasmid
pJM2 was kindly provided by T. Fox (Cornell University).
Radioactive probes were prepared by random primer
labeling and then G50 column puriﬁed. Membranes
(Hybond, Amersham) were exposed to PhosphorImager
screens (Fuji) and scanned (FujiFilm FLA 5100). Quanti-
ﬁcation of the P
32 signal was performed with the Image
Gauge imaging software supplied (Fuji).
Protein purification
About 1l of yeast cells were grown in glycerol-lactate
containing SD minimal medium to an OD600=0.5.
Protein expression was induced by shifting the cells to
galactose for 1h. After incubation in galactose medium
the expression of GFP-chimeras was checked by ﬂuores-
cence microscopy. Yeast crude extracts were obtained
from 2g of cells by the FASTPREP method. All following
steps were carried out at 48C. The cell pellet was resus-
pended in 2ml of lysis buﬀer (50mM Tris–HCl pH7.5,
100mM NaCl, 1.5mM MgCl2, 0.15% NP-40) and a pro-
tease inhibitor cocktail (0.5mM PMSF, 2mM Benzami-
dine, 1mM Leupeptin, 2mM Chymostatin and 2.6mM
Aprotinin; Sigma) was added. Cells were mixed with
glass beads (1g glass beads per gram of cell pellet) and
transferred to a FASTPREP-24 (MQ-Biogene). Cells were
broken with four pulses of vortexing (4.0m/s for 20s),
keeping the cells on ice between each pulse. Protein puri-
ﬁcation was essentially performed as described in ref. 27.
In brief, a 10-ml protein sample was injected into an
FPLC (AKTA explorer) and protein was eluted gradually
by increasing the NaCl concentration with a linear gradi-
ent from 0.26M to 1M. One-milliliter fractions were
collected and 50ml of each fraction transferred to an
Inmobilon membrane (Millipore) using a vacuum dot-
blot apparatus (Bio-Rad BioDot SF Cell) prior to GFP
detection with an anti-GFP-HRP antibody (Miltenyi
Biotec). Main peaks of mt125Top1 protein elution were
determined in fractions containing 0.294–0.316M NaCl,
and main peaks of n125Top1 protein elution were deter-
mined in fractions 0.362M from 0.384M NaCl. Two 1-ml
fractions were pooled, and protein concentration and
buﬀer exchange were achieved by a microcon YM-50
spin-column (Millipore). Samples were stored at –208C
in 50mM Tris–HCl pH7.5 with 1mM EDTA, 1mM
DTT, 0.5M NaCl and 50% glycerol.
Immunoblotting
Three microliters of mt125Top1 and 15ml of n125Top1
extracts were analyzed on an 8% Tris–glycine-SDS–poly-
acrylamide gel. Gels were either stained with Coomassie
or GFP-125Top1 fusion proteins were transferred to a
membrane (Inmobilon, Millipore) and inmuno-detected
(anti-GFP-HRP antibody, Miltenyi Biotec) according to
standard protocols.
DNA relaxation assays
DNA relaxation reactions were performed as described in
ref. 28 with the following modiﬁcations. Partially puriﬁed
enzyme preparations were incubated in 20ml reaction
volumes containing 0.3mg of negatively supercoiled
pBR322 plasmid DNA in 0.2M Tris–HCl pH7.5, 1mM
EDTA, 0.1M MgCl2 and 1M KCl. The samples were
incubated for 30min at 308C using 5 U of enzyme.
Reactions were terminated by adding 1% SDS and incu-
bated for 50min with 0.75mg/ml proteinase K. Products
were electrophoresed in a 0.8% agarose gel in 1 TBE
buﬀer and plasmid DNA was visualized by staining
with 0.5mg/ml EtBr and photographed over a UV trans-
illuminator. One unit was deﬁned as the amount of
Table 1. Plasmids
Plasmid Feature Source
pWE3 GAL1p::TOP1 (9)
pNL30 GAL1p::TOP1-103 (9)
pUG23 HIS3, MET25p::GFP::CYC1-T U. Gueldener and J.H. Hegemann
pUG34 HIS3, MET25p::GFP::CYC1-T U. Gueldener and J.H. Hegemann
pUG-MET25p HIS3, MET25p::CYC1-T Present study
pRWE085 HIS3, MET25p::SOD2MLS-GFP-125TOP1-103::CYC1-T Present study
pRWE090 HIS3, MET25p::GFP-125TOP1-103-SV40NLS::CYC1-T Present study
pRWE091 HIS3, MET25p::GFP-125TOP1-SV40NLS::CYC1-T Present study
pRWE096 HIS3, MET25p::SOD2MLS-GFP-125TOP1::CYC1-T Present study
pRS424 TRP1 (48)
pGAL1:RNH1 URA3, GAL1p::RNH1::CYC1-T A. Aguilera
pRS424-GAL1p TRP1, GAL1p::CYC1-T Present study
pRWE108 TRP1, GAL1p::SOD2MLS-GFP-125TOP1-103::CYC1-T Present study
pRWE120 TRP1, GAL1p::TOP1-GFP::CYC1-T Present study
pRWE121 TRP1, GAL1p::TOP1-103-GFP::CYC1-T Present study
pRWE123 TRP1, GAL1p::SOD2MLS-GFP-125TOP1::CYC1-T Present study
pRWE126 TRP1, GAL1p::GFP-125TOP1-103-SV40NLS::CYC1-T Present study
pRWE129 TRP1, GAL1p::GFP-125TOP1-SV40NLS::CYC1-T Present study
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supercoiled plasmid under standard reaction conditions.
DNA unwinding assays
Reaction conditions were as indicated as above but after a
30min incubation at 308C using 50 U of enzyme. CPT
(0.5mM in 1% DMSO) was added at a ﬁnal concentration
of 50mM and the incubation was prolonged for another
30min. Products were separated in 0.8% agarose in
1 TBE buﬀer containing 0.5mg/ml EtBr.
Microscopy
Cells were grown at an OD600=0.2, washed and incu-
bated in fresh, prewarmed media containing 1.15mg/ml
of MitoTracker Orange (Invitrogen) for 30min at 308C.
Then cells were washed two times with 1  PBS, and
either incubated with 1mg/ml of Hoechst33422 (Fluka) or
0.01mg/ml DAPI (Sigma) for 30min at 308C. For drug-
localization experiments cells were incubated with 20mg/
ml CPT or 20mg/ml TPT for 30min at 308C. Finally, cells
were washed again two times with 1 PBS. Confocal
images (TCS-SP5, Leica) and wide-ﬁeld images (DM-
6000B, Leica) were obtained at a 63  and 100  magniﬁ-
cation, respectively.
CHEF
DNA was extracted in low melting agarose (Pronadisa)
plugs as described (29). In-gel digestion of genomic and
mitochondrial DNA was performed as follows: plugs were
preincubated for 30min at 48C in 325ml1   restriction
buﬀer containing 10mM Tris–HCl, 10mM MgCl2,
1mM DTT and 1% BSA. Restriction buﬀer was replaced
and upon addition of 300U of ApaI (Takara Bio Inc.,
Japan) the plugs were incubated at 378C for 24h, another
300U of ApaI were added and incubation was prolonged
for 8h. Plugs were imbedded into a 0.8% (1 TAE,
0.3mg/ml EtBr) agarose gel and fragments were separated
by electrophoresis at 1.4V/cm overnight.
RESULTS
Inducible Top1 targeting to thenucleus and mitochondria
We have developed a system allowing the organelle-speci-
ﬁc targeting of DNA damage by inducible expression of
topoisomerase I (Top1), which is either directed to the
nucleus or to the mitochondria. A schematic drawing is
outlined in Figure 1A. Wild-type Top1 catalyzes a revers-
ible DNA cleavage reaction by transferring a phosphodie-
ster bond to the active site tyrosine residue (30,31).
Stabilization of the Top1–DNA complexes can either be
achieved by mutating the S. cerevisiae TOP1 and substi-
tuting arginine for a lysine at amino acid 420 [G to A
transition at nt 1259 named TOP1-103 (9)] or interaction
of the native Top1 protein with the anticancer drug CPT
(12). In both cases the stabilization of a covalently
attached Top1 to the DNA has been shown to result in
persistent DNA single-strand breaks (SSBs). While
Top1-mediated, persistent nuclear DNA damage has
been shown to inhibit cell growth (9), we reasoned that
Figure 1. Experimental approach. (A) Schematic presentation of diﬀerent possibilities for the induction of organelle-speciﬁc Top1-mediated DNA
damage. (B) Constructs used in this study. Shown are the diﬀerent promoters (GAL1p, MET25p), GFP, nuclear localization sequence (NLS) and
mitochondrial localization sequence (MLS). +1 refers to the start codon of the TOP1 open reading frame (ORF). A truncated TOP1 ORF was
named 125TOP1, and nomenclature was changed to TOP1-103 in constructs containing a single-point mutation (103, asterisk) leading to a toxic
Top1 protein.
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mation of respiration-deﬁcient ‘petite’ cells due to mito-
chondrial dysfunction.
Diﬀerent TOP1 constructs were designed for speciﬁc
targeting to the nucleus or mitochondria (Figure 1B). The
ﬁrst 375bp (125 aa) of TOP1 were deleted because seque-
nce alignment had led to the prediction of a nuclear local-
ization sequence (NLS) within this region (32). To assess
protein localization and toxicity, the full-length TOP1 or
truncated TOP1 ORFs were tagged with green ﬂuorescent
protein (GFP) at the C-terminal or N-terminal, respec-
tively. For nuclear targeting the SV40-NLS was attached
at the 30 end of the truncated 125TOP1. For mitochondrial
targeting the SOD2 mitochondrial leader sequence (MLS)
was attached at the 50 end of the GFP. To improve protein
import into the mitochondria it was necessary to place
two SOD2-MLS in front of the GFP [Figure S1, (33)].
Finally, expression of all constructs was placed under con-
trol of the inducible MET25 or GAL1 promoters (Table 1).
It is possible that accumulation of persistent nuclear
DNA SSBs mediated by a toxic Top1-103 protein might
aﬀect mRNA transcription levels. Thus, we ﬁrst analyzed
mRNA expression levels of GAL1 promoter driven con-
structs by northern analysis (Figure 2A). TOP1-103,
n125TOP1-103 and mt125TOP-103 mRNAs were not
detectable in cells grown in glycerol (no induction) and
glucose (repression), while shifting cells to galactose
(induction) led to the rapid appearance of mRNAs.
In all constructs, expression levels reached a maximum
within 60min (Figure 2B) and mRNA expression levels
remained high within 180min. No signiﬁcant diﬀerence
in mRNA levels was obtained comparing expression of
n125TOP1-103 with mt125TOP-103, or expression of the
TOP-103 constructs with a TOP1 expressing control
vector (data not shown). From these results we conclude
that nuclear targeting of the Top1-103 protein does not
aﬀect TOP1-103 transcription levels within 180 min of
induction.
Figure 2. Localization sequences target Top1p either to the nucleus or mitochondria. (A) Northern blot analysis of TOP1 mRNA upon galactose-
induced gene expression. (B) Relative quantiﬁcation of TOP1 mRNA levels. Relative TOP1 mRNA levels were normalized to 25S mRNA. The value
obtained at time point 0 was set as 1. Average values of two independent experiments are shown. (C) Projection of a series of focal plane images
derived from confocal ﬂuorescence microscopy. GFP-Top1 expression was induced for 30min in galactose (green). The nucleus and mitochondria
were localized with Hoechst33342 (blue) and Mitotracker (red) dyes, respectively. White bar represents 5mm. Control cells grown in glucose did not
exhibit green ﬂuorescence (data not shown).
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Top1-103 chimeras, expression was induced for 30min in
galactose and localization was monitored by confocal
microscopy (Figure 2C). The Top1-103 tagged at the
N-terminal with a GFP and C-terminal with a SV40-
NLS (n125Top1-103) localized to nucleus (visualized by
the turquoise merge of green and blue). This localization is
in agreement with that of Top1 tagged at the C-terminal
with a GFP (34). Importantly, GFP signal was absent
from mitochondria. In contrast, expression of the trun-
cated TOP1 bearing a SOD2-MLS (mt125Top1-103) led
to an accumulation of GFP signal within the mitochon-
dria, as seen by a punctuated pattern that overlays with
the mitochondrial Mitotracker staining (visualized by the
yellow merge of green and red). Notably, GFP signal in
the nucleus was not detectable. Growth in glucose is suf-
ﬁcient to suppress mRNA expression to an extent which
abolishes detection of GFP signal (data not shown). Thus,
by attaching of a speciﬁc localization signal the Top1 pro-
tein can be exclusively targeted either to the nucleus or the
mitochondria.
Organelle-specific targeting of atoxic 125Top1-103
proteininduces cell death, or petiteformation andmtDNA
depletion
Growth inhibition on nonfermentable carbon sources
such as glycerol is a hallmark of respiration deﬁcient
rho
 , so-called ‘petite’ cells (35). In order to test the
eﬀect of nuclear or mitochondrial targeting of the
Top1-103 protein on cell viability and respiration capacity
we placed expression of the bio-ﬂuorescent Top1-103 chi-
mera under control of the MET25 promoter. This pro-
moter has the advantage that cells can be grown in
medium with diﬀerent carbons sources because its expres-
sion is induced in the absence of methionine. As shown in
the drop test in Figure 3, targeting of n125Top1-103 to the
nucleus greatly reduced growth and viability of cells.
Targeting of mt125Top1-103 to the mitochondria did
not aﬀect cell viability in fermentable medium (glucose).
However, the accumulation of a red pigmentation charac-
teristic of ade2
  cells was suppressed and instead, white-
colored colonies were obtained. The appearance of white
colonies is an indication of respiration-deﬁcient petite cells
where mitochondria are not functional. Accordingly,
the formation of petite cells was conﬁrmed by growth
inhibition in nonfermentable medium (glycerol). Thus,
targeting of Top1-103-mediated SSBs to the nucleus
aﬀects cells viability, while mitochondrial targeting
induces petite cells.
Respiration-deﬁcient petite cells result from the loss of
nuclear encoded functions, which are essential for the
mitochondrial respiration capacity, or from mtDNA rear-
rangement, mutation or loss. Targeting of the toxic
mt125Top1-103 to mitochondria results in mtDNA
damage, which is predicted to impede mtDNA replication
and to promote mtDNA loss. In order to quantify the
extent of respiration-deﬁcient cells, the mt125TOP1-103
construct placed under the control of the GAL1 promoter
was expressed up to 48h, and petite formation was
assayed by visual inspection of white-versus red-pigmen-
ted colonies as well as growth inhibition in nonfermenta-
ble medium at the indicated time-point (Figure 4A).
Within 48h of mt125Top1-103 expression, conversion of
wild-type into petite cells was nearly complete. About
97% of colonies expressing mt125Top1-103 turned white
(7% in the control) and only 15% of the colonies were
proﬁcient to form colonies in nonfermentable medium
(99% in the control). We wondered if the observed time-
dependent increase in petite cells was due to the formation
of respiration-deﬁcient but mtDNA-containing rho
– or
due to the appearance of mtDNA-less rho8 cells, respec-
tively. Therefore, DNA was extracted in agarose plugs, in-
gel digested with ApaI and analyzed by Southern blot
(Figure 4B). After hybridization with a probe speciﬁc for
the mitochondrial COX2 gene, a clear drop in mtDNA
was seen after 48h expression of the mt125Top1-103 con-
struct (compare signals obtained for nuclear and mtDNA
after 48h of cellular growth in galactose or glucose).
Quantiﬁcation of the mtDNA content in respect to
nuclear DNA (Figure 4C) showed that the overall
mtDNA content was reduced to about 25% within 48h
of growth in galactose. To conﬁrm that prolonged
mt125Top1-103 expression induces the formation of rho8
cells, cells expressing mt125Top1-103 for 48h were stained
with the DNA-intercalating agent DAPI and analyzed by
ﬂuorescence microscopy. In vivo staining of mtDNA by
DAPI was practically absent in a high percentage of
cells (see example in Figure 4D and Figure S2) conﬁrming
that mt125Top1-103 expression leads to mtDNA less
rho8 cells.
Figure 3. Drop test assay to assess the eﬀect of nuclear and mitochondrial expression of MET25p-driven constructs. Targeting of the toxic
n125Top1-103 to the nucleus leads to growth inhibition in fermentable (glucose) and nonfermentable (glycerol) growth medium. Targeting of the
toxic mt125Top1-103 to mitochondria leads to growth of white colonies in glucose and growth inhibition in glycerol, both of which indicate the
formation of respiration deﬁcient ‘petite’ cells.
e26 Nucleic Acids Research,2009, Vol. 37,No. 4 PAGE6 OF12CPT isnot capable ofinteracting withmitochondrial Top1p
As outlined before, another approach to induce persistent
SSBs takes advantage of the anticancer drug CPT. To test
the eﬀect of CPT on organelle-speciﬁc Top1 targeting,
MET25-promoter-driven constructs were used. Drop test
assays revealed that upon targeting of n125Top1 to the
nucleus, cellular growth was completely inhibited in the
presence of CPT (Figure 5A). Interestingly, targeting of
mt125Top1 to the mitochondria neither led to the appear-
ance of white colonies nor impeded cellular growth in
nonfermentable medium. This result can be interpreted
in two ways: the mitochondrial mt125Top1 is not func-
tional, or that CPT cannot interact with the mt125Top1
protein. In order to test for these possibilities, the
mt125Top1 and n125Top1 proteins were puriﬁed from
top1D yeast cells. The proteins were enriched in a two-
step protocol by selective ammonium-sulfate precipitation
and by FPLC using a Mono S column as described pre-
viously [(27), for detailed description see ‘Materials and
Methods’ section)]. Western blot analysis using an anti-
GFP antibody led to a strong ﬂuorescent signal
Figure 4. Mitochondrially targeted mt125Top1-103 leads to mtDNA loss and the formation of rho8 petite. (A) Time course of mt125Top1-103
dependent petite formation. Cells were grown in galactose-containing liquid medium (expression). At the indicated times cells were retrieved, grown
on glucose containing plates (no expression) and replica-plated onto glycerol. Petite cells were determined by color (white; open diamonds) and their
inability to grow on glycerol (black diamonds). Average values of two independent experiments are shown. (B) CHEF analysis of the mtDNA copy
number. In-plug isolated, total cellular DNA was ApaI digested, gel electrophoresed and analyzed by Southern blot. Shown are the agarose gel
before Southern blotting (rDNA fragments, open triangle) and the signals obtained using a speciﬁc probe against mitochondrial (right top, black
triangle) and nuclear DNA (right bottom) after Southern blotting. (C) Determination of the relative mtDNA copy number. The mtCOX2 hybrid-
ization signal obtained at time point 0 was normalized to the nuclear probe and set as 100%. Average values of two independent experiments are
shown. (D) Wide-ﬁeld ﬂuorescence microscopy analysis of petite cells after 48h of mt125Top1-103 expression. DAPI (white) and Mitotracker (red)
staining of rho
+ (w/o induction) and rho8 (48h of induction) is shown. White bar represents 5mm.
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114.4kDa (Figure 5B top, arrows), which approximately
corresponds to the expected molecular weight of the pro-
tein chimeras (expected molecular weight: n125Top1=
104.98kDa, mt125Top1=103.66kDa). Coomassie-stain-
ing of a protein gel run in parallel revealed enrichment
of a speciﬁc band (bottom, arrow) migrating at about
the same size, as well as the presence of a few contaminant
proteins. From these results we conclude that the two-
step puriﬁcation protocol led to highly enriched Top1
proteins. In order to test for CPT sensitivity of the
nuclear and mitochondrial Top1 proteins, a plasmid
relaxation assay was carried out and the products were
analyzed in the presence and absence of EtBr (36)
(Figure 5C). Incubation of supercoiled plasmid DNA
with nuclear and mitochondrial Top1 led to the formation
of relaxed topoisomers as visualized in an agarose gel
without EtBr (lanes 2 and 3). Importantly, electrophoresis
of DNA treated with nuclear and mitochondrial
Top1 proteins in the presence of EtBr shows an
increase of relaxed plasmid (RL, lanes 6 and 8). In the
presence of CPT in the reaction, a fraction of the relaxed
plasmid was converted into nicked, open circular plasmid
DNA (OC, lanes 7 and 9). Thus, the nuclear n125Top1
protein is sensitive to CPT in vivo and in vitro, but the
mitochondrial mt125Top1 protein is only sensitive to
CPT in vitro.
Topotecan leads to petiteformation and accumulates in
yeast mitochondria
While yeast cells are sensitive to CPT treatment, it has
been shown that CPT analogs which are soluble in aque-
ous solutions are much less toxic to yeast cells (37). One
such analog is the anticancer drug TPT that induces apop-
tosis of mammalian tumor cells (38). From microscopic
studies it has been inferred that TPT is enriched in mito-
chondria of mammalian cells (39). We reasoned that the
water solubility and positive charge of the TPT molecule
(15) could also allow the drug to penetrate mitochondria
of S. cerevisiae. Indeed, expression of mt125Top1 in the
presence of TPT led to the formation of petite cells
(Figure 6A) indicating that TPT reaches the mitochondria
Figure 5. CPT has no eﬀect on mitochondrially targeted mt125Top1 protein. (A) Drop test analysis of cell viability in cells expressing 125TOP1
constructs in the presence of CPT. (B) Western analysis of n125Top1 and mt125Top1 puriﬁed from yeast. Protein size was determined using an anti-
GFP antibody and HRP substrate (top left) and inferred from a coloration of the membrane upon incubation with the antibody (top right, arrows).
Coomassie blue staining shows a signiﬁcant enrichment for 125Top1 proteins (bottom, arrow). (C) Biochemical characterization of 125Top1p activity
by in vitro DNA relaxation assays. Arrows indicate supercoiled (SC), relaxed (RL), linear (L) and open circular (OC) forms of plasmid analyzed in
the presence (lanes 1 to 3) or absence (lanes 4 to 10) of EtBr. Both n125Top1 and mt125Top1 led to the formation of topoisomers (lanes 2 and 3)
and to open circular DNA in the presence of CPT (lanes 7 and 9).
e26 Nucleic Acids Research,2009, Vol. 37,No. 4 PAGE8 OF12in an active form. We determined petite formation by
replica-plating of single colonies grown on galactose
onto glycerol-containing medium. By counting the colo-
nies growing on glycerol, we found that expression of
mt125Top1 in the presence of TPT led to induction of
more than 95% petite thus being as potent in generating
petite as expression of mt125Top1-103.
To enforce the idea that impaired penetration of CPT
through mitochondrial membranes impedes the formation
of ternary Top1-mtDNA-CPT complex in yeast cells, we
determined the subcellular localization of CPT and TPT in
yeast cells (Figure 6B). Therefore, we took advantage of
the autoﬂuorescence of CPT and TPT to visualize their
subcellular localization (40). Without CPT or TPT
Figure 6. Topotecan is capable of inducing petite and accumulates in mitochondria. (A) Drop test assay to test the eﬀect of TPT treatment on yeast
growth. The indicated constructs were expressed under control of the GAL1 promoter and cells were grown in plates without or with 20mg/ml TPT.
Note that petite induced in galactose by expression of mt125Top1-103 under control of the GAL1p grew slower than petite induced in galactose by
expression of mt125Top1-103 under control of the MET25p (Figure 3). (B) Intracellular localization of CPT and TPT. Using the settings for the
detection of DAPI, the intracellular TPT and CPT localization was determined by their auto-ﬂuorescence. Construct pRWE129 was expressed for
GFP-localization of the nucleus. CPT is mainly enriched in vacuoles while TPT ﬂuorescence and Mitotracker staining co-localized (white arrow).
Cells without Mitotracker straining were used as control to discard the possibility that we detect TPT auto-ﬂuorescence applying the Mitotracker
settings. White bar represents 5mm.
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treated cells we could see an accumulation of ﬂuorescence
in the vacuoles while a clear accumulation of ﬂuorescence
in mitochondria was observed in TPT-treated cells. The
mitochondrial TPT ﬂuorescence was not dependent on the
Mitotracker staining because it could be detected in the
absence of Mitotracker. Thus, our results show that TPT
accumulates in yeast mitochondria and that the formation
of a toxic, ternary complex between Top1-TPT and
mtDNA leads to petite formation.
DISCUSSION
The goal of this study has been the development of an
experimental system allowing the induction of organelle-
speciﬁc DNA damage. We show that this can be achieved
by inducible expression of a toxic TOP1-103 allele tagged
either with a nuclear or mitochondrial localization
sequence. Consequently, nuclear DNA damage led to
cell death while mtDNA damage led to loss of mtDNA
and rho8 petite formation. In addition (by inducible
expression of a TOP1), we determined that CPT and its
derivative TPT are mainly targeting DNA damage to
nuclear or mitochondrial DNA, respectively. This ﬁnding
shows that modifying a DNA-damaging drug might have
an important impact on its intracellular distribution.
Addition of multiple SOD2-MLS and partial truncation
of a NLS within the N-terminal part of Top1 appeared to
be crucial for the targeting of Top1 to mitochondria, while
targeting of the N-terminal truncated S. cerevisiae Top1
protein to the nucleus could be achieved by adding an
SN40 nuclear localization sequence (Figure S1). The N-
terminal truncated Top1 targeted to the nucleus remained
as sensitive as wild-type Top1 to CPT both in vivo and
in vitro. Interestingly, deletion of an even larger portion of
the human Top1N-terminal domain [up to residue 190,
(41)] has been shown to result in a truncated enzyme
retaining full catalytic activity. From this result we infer
that the basic structural properties of the truncated
125Top1 remain intact. Worthy of note, in addition to
DNA nicking and ligation, the partially enriched nuclear
125Top1 had an unexpected in vitro activity. This activity
was seen by the formation of linear plasmid DNA in a
CPT-independent manner (Figure 5C). In the FPLC salt
gradient, the n125Top1 protein always eluted several frac-
tions ahead of the mt125Top1 protein (data not shown).
The additional activity of the n125Top1 protein fraction
might be due to a contaminant, or n125Top1 may be
subjected to post-translational protein modiﬁcations in
the nucleus, which do not occur in the mitochondria.
Previously described cis-o rtrans-acting activities present
in the N-terminal region of Top1 include binding sites for
interacting proteins (42), and putative target sequences for
protein phosphorylation (43).
Although targeting of the 125Top1 protein to the
nucleus is cytotoxic in the presence of CPT, mitochondrial
targeting of 125Top1 failed to generate petite cells by CPT
treatment. One possibility is that CPT-mediated mtDNA
damage might be very eﬃciently repaired. Since cells lack-
ing the BER enzyme ApnI did not generate petite upon
CPT treatment (data not shown), it is less likely that CPT-
mediated DNA damage is eﬃciently repaired by BER.
Other possibilities are that CPT is excluded from mito-
chondria by drug transporters or that CPT is unable to
pass the mitochondrial membranes. Upon CPT treatment,
Top1-induced DNA nicks have been shown to account for
the formation of replication-mediated DNA DSBs (44).
Monitoring the inhibition of yeast growth it has been
shown that the biological activity of CPT is at least
10-fold higher than that of TPT [(37) and data not
shown]. Thus, it is unlikely that CPT-mediated mtDNA
damage would be more eﬀectively repaired than TPT-
mediated mtDNA damage. Our ﬁnding that CPT accumu-
lates in the vacuoles and TPT in the mitochondria favor
the possibility that the water and organic solvents insolu-
ble CPT (11) is unable to penetrate the mitochondrial
membrane. To easily pass mitochondrial membranes
molecules have to be positively charged and water-soluble
such as ethidium bromide (EtBr), lipophilic carcinogens
(22,45,46) or the water-soluble, positively charged CPT
analog TPT (15). Consequently, only nuclear DNA
appears to be susceptible to the toxic eﬀects mediated by
CPT treatment. If the mitochondrial membrane exhibits a
barrier to the passage of CPT, depending on their chem-
ical structure, this might also be true for other CPT
analogs.
TPT accumulates in mitochondria and induces respira-
tion-deﬁcient petite cells when S. cerervisiae mitochondria
are provided with Top1. We found that TPT treatment of
wild-type cells fails to induce petite (data not shown). This
result implies that Top1 is not present in S. cerevisiae
mitochondria and opens the possibility that other enzy-
matic activities, such as Top3, substitute for the lack of
Top1 in this organelle. In mammalian cells the mitochon-
drial accumulation of TPT could account in part for its
anticancer activity. In line with this ﬁnding, the chemical
properties of the CPT derivate SN-38 would predict that it
is capable of passing the mitochondrial membrane barrier.
Indeed, treatment of carcinoma-derived cell lines with SN-
38 has been shown to induce the loss of mitochondrial
membrane potential as well as mitochondrial membrane
permeability transition (47). If we anticipate that mtDNA
is a main target for Top1-mediated DNA damage, it
would be evident that a functional mtTop1 is required
for the full anticancer activity of water-soluble CPT deri-
vatives. Human cells encode for a mitochondria-speciﬁc
Top1 (6) and it would be very interesting to check if
cells lacking this enzymatic activity would be more resis-
tant to TPT treatment. One might speculate that muta-
tions in the human mtTop1 could impair its interaction
with TPT leading to increased resistance of cancer cells
against therapeutic treatment. Tissue-speciﬁc mtTop1
expression levels might also alter the impact of TPT
treatment.
We present a novel method for the organelle-targeted
induction of Top1p-mediated DNA damage. This system
can be easily applied to studies in human cells and pro-
vides the means to further advance our knowledge about
mitochondria-speciﬁc DNA damage repair and check-
point responses.
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